Study Evaluating MYO-029 in Adult Muscular Dystrophy

The purpose of this phase I/II, multicenter, safety trial is to study MYO-029 in adult patients with muscular dystrophy.

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Becker Muscular Dystrophy Congenital, Hereditary, and Neonatal Diseases and Abnormalities Facioscapulohumeral Muscular Dystrophy Genetic Diseases, Inborn Genetic Diseases, X-Linked Limb-girdle Muscular Dystrophy Muscular Diseases Muscular Disorders, Atrophic Muscular Dystrophies Muscular Dystrophies, Limb-Girdle Muscular Dystrophy, Duchenne Muscular Dystrophy, Facioscapulohumeral Musculoskeletal Diseases Nervous System Diseases Neuromuscular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Washington D.C., District of Columbia, United States

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Written informed consent.
Confirmed clinical and molecular diagnosis of Becker Muscular Dystrophy (BMD), Facioscapulohumeral Muscular Dystrophy (FSHD), or Limb-Girdle Muscular Dystrophy (LGMD)
Independently ambulatory

Exclusion criteria

Patients with certain clinical conditions
Patients using steroids or other medications with the potential to affect muscle function
History of sensitivity to monoclonal antibodies or protein pharmaceuticals
Pregnant or lactating women.

Treatment and study plan

MYO-029

Drug

Primary outcomes

Safety assessment

Sponsors and collaborators

Lead sponsor

Wyeth is now a wholly owned subsidiary of Pfizer

Industry

Registry information

Important dates

Study start: 2005
Study completion: 2007
First posted: Feb 23, 2005
Registry last updated: Dec 28, 2007

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed